ceuticals to
discontinue the development of its product candidates; and risks related to
the uncertain and time-consuming regulatory approval process. These and
other risk factors are discussed under "Risk Factors," in the Quarterly
Report on Form 10-Q for the quarter ended June 30, 2007 filed by Jazz
Pharmaceuticals with the Securities and Exchange Commission on August 10,
2007. Jazz Pharmaceuticals undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of new
information, future events or changes in its expectations.
JAZZ PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
Revenues:
Product sales, net $13,436 $11,184 $38,676 $31,409
Royalties, net 253 150 824 336
Contract revenue 7,785 162 10,326 662
Total revenues 21,474 11,496 49,826 32,407
Operating expenses:
Cost of product sales 1,938 2,044 5,620 5,367
Research and development 16,978 14,746 49,252 41,920
Selling, general and
administrative 18,069 12,906 50,583 38,841
Amortization of intangible
assets 2,287 2,400 6,936 7,200
Provision for government
settlement - - 17,469 -
Total operating expenses 39,272 32,096 129,860 93,328
'/>"/>SOURCE Jazz Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine news :1.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma2.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference3.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.4.
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study5.
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum6.
ACG Announces Major Gift by Salix Pharmaceuticals, Inc.7.
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors8.
Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo9.
HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness10.
CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael11.
UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West